Teva Pharmaceutical Industries Limited (TEVA)

NYSE: TEVA · Real-Time Price · USD

36.36

-0.26 (-0.71%)

At close: Sep 4, 2026, 4:00 PM EDT

37.19

+0.83 (2.28%)

After-hours: Sep 4, 2026, 7:59 PM EDT

Teva Pharmaceutical Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	3,655	3,556	3,300	3,226	2,801	2,165
Cash & Short-Term Investments	3,655	3,556	3,300	3,226	2,801	2,165
Cash Growth	69.14%	7.76%	2.29%	15.17%	29.38%	-0.55%
Receivables	3,493	3,709	3,059	3,408	3,696	4,529
Inventory	3,221	3,179	3,007	4,021	3,833	3,818
Prepaid Expenses	1,034	1,122	1,006	1,255	1,162	1,075
Restricted Cash	-	-	-	1	33	33
Other Current Assets	2,357	2,380	2,180	574	526	953
Total Current Assets	13,760	13,946	12,552	12,485	12,051	12,573
Property, Plant & Equipment	4,261	4,425	4,948	6,147	6,158	6,477
Long-Term Investments	-	-	-	8	-	-
Goodwill	15,839	16,000	15,147	17,177	17,633	20,040
Other Intangible Assets	3,447	3,781	4,418	5,387	6,270	7,466
Long-Term Deferred Tax Assets	2,162	2,191	1,799	1,812	1,458	596
Other Long-Term Assets	388	405	462	463	441	514
Total Assets	39,857	40,748	39,326	43,479	44,011	47,666

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Accounts Payable	2,721	2,531	2,203	2,602	1,887	1,686
Accrued Expenses	5,701	6,081	5,651	5,525	4,955	5,280
Current Portion of Long-Term Debt	4,500	1,820	1,781	1,672	2,109	1,426
Current Portion of Leases	-	94	87	97	93	109
Other Current Liabilities	2,724	2,930	3,074	2,351	2,425	2,526
Total Current Liabilities	15,646	13,456	12,796	12,247	11,469	11,027
Long-Term Debt	12,112	15,005	16,002	18,161	19,103	21,617
Long-Term Leases	282	311	314	343	371	441
Pension & Post-Retirement Benefits	-	50	63	73	-	-
Long-Term Deferred Tax Liabilities	289	296	483	606	548	784
Other Long-Term Liabilities	3,771	3,716	3,948	3,923	3,922	2,553
Total Liabilities	32,100	32,834	33,606	35,353	35,413	36,422

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Common Stock	59	58	58	57	57	57
Additional Paid-In Capital	28,256	28,133	27,764	27,807	27,688	27,561
Retained Earnings	-13,969	-13,762	-15,173	-13,534	-12,975	-10,529
Treasury Stock	-4,128	-4,128	-4,128	-4,128	-4,128	-4,128
Comprehensive Income & Other	-2,465	-2,391	-3,148	-2,696	-2,838	-2,683
Total Common Equity	7,753	7,910	5,373	7,506	7,804	10,278
Minority Interest	4	4	347	620	794	966
Shareholders' Equity	7,757	7,914	5,720	8,126	8,598	11,244
Total Liabilities & Equity	39,857	40,748	39,326	43,479	44,011	47,666

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Total Debt	16,894	17,230	18,184	20,273	21,676	23,593
Net Cash (Debt)	-13,239	-13,674	-14,884	-17,047	-18,875	-21,428
Net Cash Growth	-	-	-	-	-	-
Net Cash Per Share	-11.38	-11.76	-13.16	-15.23	-17.00	-19.36
Filing Date Shares Outstanding	1,165	1,150	1,134	1,121	1,111	1,103
Total Common Shares Outstanding	1,165	1,150	1,134	1,121	1,111	1,103
Working Capital	-1,886	490	-244	238	582	1,546
Book Value Per Share	6.65	6.88	4.74	6.70	7.02	9.32
Tangible Book Value	-11,533	-11,871	-14,192	-15,058	-16,099	-17,228
Tangible Book Value Per Share	-9.90	-10.32	-12.52	-13.43	-14.49	-15.61
Land	-	258	213	246	246	262
Buildings	-	2,327	1,968	2,488	2,463	2,568
Machinery	-	5,846	5,480	7,226	7,349	7,359
Construction In Progress	-	377	1,330	1,427	1,199	1,034

SEC Filings: 10-K · 10-Q